Ron Leuty is a Senior Reporter at SF Business Times. He covers a range of topics within the biotech sector, including medicine and healthcare, pharmaceuticals, and business economics, with a particular focus on medical technology innovations and corporate finance. Ron's work has been featured in notable publications such as Yahoo Finance, San Jose Business Journal, and the Washington Business Journal.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
San Francisco, United States (Local)
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ron Leuty
BioMarin Pharmaceuticals is paying $275 million upfront for a Dutch company's experimental drug that could become the first pill-based treatment for a rare genetic bone disease that currently requires patients to inject themselves up to six times per week.
By: Ron Leuty
An S.F. startup plans to turn $115 million into a new kind of treatment for a deadly disease. Find out about the Goldman Sachs veteran leading the charge.
By: Ron Leuty
Off the clock: How Ultragenyx's new $2.7 million therapy targets patients with a rare genetic disease
By: Ron Leuty
Fast-growing biotech manufacturer loses major customer, plans layoffs
By: Ron Leuty
A new CEO is swinging Jazz Pharmaceuticals' beat.
By: Ron Leuty
A year into Renee Gala's tenure as CEO, the company could score a new approval for a drug it licensed under its previous leader.
By: Ron Leuty
Here's where a fast-growing Bay Area company is cutting jobs.
By: Ron Leuty
One of the Bay Area's most storied biotech companies plans a massive new R&D center to kick off the reimagining of its Peninsula headquarters.
By: Ron Leuty
Ultragenyx vows 'significant' cuts after experimental rare-disease drug fails late-stage clinical trial
By: Ron Leuty
The Bay Area's biotech sector has struggled in recent years, but a summer revival could signal brighter days ahead.
